Home About Us Management Product Pipeline Collaborators Contact Us


About Us; Our Programs


About 30% of all cancer deaths are due to excessive loss of muscle and body weight, called cachexia. A cachectic cancer patient cannot tolerate the required treatment leading to early death. Cachexia starts early, and today’s clinical practice cannot deal with it. We discovered, using relevant human tumor models that cachexia can be prevented by PLAP if treatments start early when the tumor is still small.


Cancer therapies are toxic to the bone marrow. Using relevant animal models, we showed that PLAP can greatly reduce therapy induced loss of platelets as well as red and white blood cells primarily by protecting their blood stem cell precursors.


The combined positive effects of PLAP on cachexia and bone marrow health will allow the use of higher doses of cancer therapies with greater frequency resulting in longer survival or even a cure.